Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

10 Nov 2023
www.biospace.com
Clinical StudyIND
SAN DIEGO & SHANGHAI--(BUSINESS WIRE)-- Sirius Therapeutics today announced it has submitted an application in Australia to begin a first-in-human clinical trial of SRSD107, its next generation siRNA therapeutic for the prevention and treatment of thromboembolic disorders. SRSD107, which specifically targeting coagulation factor XI (FXI), is the first Sirius-developed compound to reach clinical stage of development globally. “We have made rapid progress in developing SRSD107 and other candidates in our pipeline since Sirius was established two years ago. This submission marks our transition from discovery to clinical stage development,” said Dr. Qunsheng Ji, Sirius Therapeutics Chief Executive Officer. “The exceptional durability of pharmacology and safety pro SRSD107 has the potential to be a Best- and First-in-class FXI siRNA therapeutic. We aspire to develop SRSD107 as a transformative medicine with a dosing schedule of once semiannually or potentially annually for patients who need chronic anticoagulant.” About Thromboembolic Disorders Thrombosis is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism (VTE). According to a study in The Lancet of reginal and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1. About SRSD107 SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. Preclinical in vivo studies demonstrated near 100% reduction of FXI levels for up to 6 months, without bleeding events after a single subcutaneous dose. About Sirius Therapeutics Sirius is an innovative biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team. [1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128. View source version on businesswire.com: Contacts info@siriusrna.com Source: Sirius Therapeutics View this news release online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.